GSK Opens Rare Diseases Portfolio with Prosensa’s DMD Candidate
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 10 (Table of Contents)
Published: 24 Oct-2009
DOI: 10.3833/pdr.v2009.i10.1261 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
GlaxoSmithKline (GSK) and Prosensa have agreed to develop and commercialise RNA-based therapeutics for Duchenne Muscular Dystrophy (DMD)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS